medicines for Ireland



Statement on the War in Ukraine from Medicines for Europe

Medicines for Europe is highly concerned by the impact of the war in Ukraine on the supply of medicines to patients. The priority of Medicines for Europe members is to continue to ensure that patients in Ukraine and refugees arriving in EU Member States have access to the medicines and medical materials they need.

Access to life saving generic and biosimilar medicines via humanitarian corridors is and will be essential in the coming weeks and months. These should remain available to all patients regardless of where they may be and so must continue to be exempt from sanctions.

Medicines for Europe members are engaging with authorities and NGOs on the ground to secure the supply of medicines and medical supplies. Medicines for Europe is in contact with the Ukrainian government and companies operating in Ukraine to assess what medicines are needed and to request supply from our member companies. It is critical that corridors are open for the supply of medicines to Ukraine.

In parallel, Medicines for Europe is currently monitoring the European Union supply chain and any possible disruptions in collaboration with the European Medicines Agency.

We are committed to providing access to medicines on humanitarian grounds to all those in need.


Medicines for Europe
Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information please follow us at and on Twitter @medicinesforEU.


Statement on the war in Ukraine